… evaluate the pattern of clinical use of three EGFR TKIs (afatinib, gefitinib, and erlotinib). We
found that gefitinib was more commonly used than erlotinib or afatinib in Korea, especially for …

… mutations. To the best of our knowledge, this is the first study worldwide to compare the
efficacy of erlotinib, gefitinib, and afatinib in patients with rare and common EGFR mutations. …

… In this study population, mutations were more frequent in non-smokers than smokers (59.4%
vs. 39.2%, p < 0.001), in adenocarcinomas than non-adenocarcinomas (55.1% vs. 25.7%, p …

… with common EGFR mutations (ie exon 19 deletion or EGFR … As with erlotinib and gefitinib,
patients with EGFR exon 19-… – 0.44) than patients with EGFR L858R-mutant tumors (HR 0.73, …

… EGFR mutations with sensitivity to the TKI, gefitinib (17, 18). … inhibitor, erlotinib, contain
similar types of EGFR mutations. … taking gefitinib or erlotinib contain mutations in the EGFR TK …

… Subsequent discovery of activating mutations of EGFR in a subset of patients with NSCLC …
the EGFR mutation was associated with increased sensitivity to TKIs and was most common in …

… gefitinib and erlotinib in patients with pulmonary adenocarcinoma, whose tumor EGFR mutation
… predictors commonly used, males had a 67.6% mutation rate and females had a 62.9% …

… We thank the patients, investigators, study nurses, and the leadership of the CTONG who
participated in this study, as well as the laboratory that conducted the EGFR mutation testing (…

… EGFR mutation status had been confirmed and who all received 250 mg gefitinib or 150 mg
erlotinib … liver dysfunction and nail change were more frequent in the gefitinib group (n = 107)…

… The current clinical experience with the use of gefitinib and erlotinib in EGFR mutated
patients indicates that exon 19 deletion and L858R-bearing tumors commonly display …